Terms: = Ovarian cancer AND ERCC3, RAD25, 2071, ENSG00000163161, GTF2H, TFIIH, BTF2, P19447, XPB
28 results:
1. Clinical characteristics and survival outcomes in patients with primary ovarian carcinoid: A historical cohort study.
Kong S; Sun J; Sui X; Zhang S; Qi Y; Ma Y; Li S
Acta Obstet Gynecol Scand; 2023 Jul; 102(7):935-941. PubMed ID: 37059424
[TBL] [Abstract] [Full Text] [Related]
2. ercc3, a new ovarian cancer susceptibility gene?
Stradella A; Del Valle J; Rofes P; Vargas-Parra G; Salinas M; González S; Montes E; López-Doriga A; Gómez C; de Cid R; Darder E; Teulé A; Solanes A; Munté E; Capellà G; Pineda M; Feliubadaló L; Brunet J; Lázaro C
Eur J Cancer; 2020 Dec; 141():1-8. PubMed ID: 33125943
[TBL] [Abstract] [Full Text] [Related]
3. Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings.
Bonache S; Esteban I; Moles-Fernández A; Tenés A; Duran-Lozano L; Montalban G; Bach V; Carrasco E; Gadea N; López-Fernández A; Torres-Esquius S; Mancuso F; Caratú G; Vivancos A; Tuset N; Balmaña J; Gutiérrez-Enríquez S; Diez O
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2495-2513. PubMed ID: 30306255
[TBL] [Abstract] [Full Text] [Related]
4. Clinicopathological and Prognostic Significance of cancer Stem Cell Markers in ovarian cancer Patients: Evidence from 52 Studies.
Tao Y; Li H; Huang R; Mo D; Zeng T; Fang M; Li M
Cell Physiol Biochem; 2018; 46(4):1716-1726. PubMed ID: 29730663
[TBL] [Abstract] [Full Text] [Related]
5. Clinicopathological Characteristics of Mitotically-active Cellular Fibroma of the Ovary: A Single-institutional Experience.
Kim JY; Na K; Kim HS
Anticancer Res; 2017 May; 37(5):2557-2564. PubMed ID: 28476827
[TBL] [Abstract] [Full Text] [Related]
6. Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer.
Tedaldi G; Tebaldi M; Zampiga V; Danesi R; Arcangeli V; Ravegnani M; Cangini I; Pirini F; Petracci E; Rocca A; Falcini F; Amadori D; Calistri D
Oncotarget; 2017 Jul; 8(29):47064-47075. PubMed ID: 28423363
[TBL] [Abstract] [Full Text] [Related]
7. [Clinical-based study of ovarian cancer patients with and without BRCA1/2 genes mutation: clinical features and pedigree analysis].
Tao T; Yang JX; Shen K; Cao DY
Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):20-25. PubMed ID: 28190311
[No Abstract] [Full Text] [Related]
8. Ataxia-Telangiectasia and RAD3-Related and Ataxia-Telangiectasia-Mutated Proteins in Epithelial ovarian Carcinoma: Their Expression and Clinical Significance.
Lee B; Lee HJ; Cho HY; Suh DH; Kim K; No JH; Kim H; Kim YB
Anticancer Res; 2015 Jul; 35(7):3909-16. PubMed ID: 26124337
[TBL] [Abstract] [Full Text] [Related]
9. Evaluation of the Hematologic Safety of Same Day Versus Standard Administration (24- to 72-Hour Delay) of Pegfilgrastim in Gynecology Oncology Patients Undergoing Cytotoxic Chemotherapy.
Billingsley CC; Jacobson SN; Crafton SM; Crim AK; Li Q; Hade EM; Cohn DE; Fowler JM; Copeland LJ; Salani R; Backes FJ; O'Malley DM
Int J Gynecol Cancer; 2015 Sep; 25(7):1331-6. PubMed ID: 26067861
[TBL] [Abstract] [Full Text] [Related]
10. Correlations among ERCC1, xpb, UBE2I, EGF, TAL2 and ILF3 revealed by gene signatures of histological subtypes of patients with epithelial ovarian cancer.
Guo Y; Fu P; Zhu H; Reed E; Remick SC; Petros W; Mueller MD; Yu JJ
Oncol Rep; 2012 Jan; 27(1):286-92. PubMed ID: 21971700
[TBL] [Abstract] [Full Text] [Related]
11. Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.
Fleming ND; Agadjanian H; Nassanian H; Miller CW; Orsulic S; Karlan BY; Walsh CS
Cancer; 2012 Feb; 118(3):689-97. PubMed ID: 21751198
[TBL] [Abstract] [Full Text] [Related]
12. Influence of perceived breast cancer risk on screening behaviors of female relatives from the Ontario site of the Breast cancer Family Registry.
Zhang LR; Chiarelli AM; Glendon G; Mirea L; Edwards S; Knight JA; Andrulis IL; Ritvo P
Eur J Cancer Prev; 2011 Jul; 20(4):255-62. PubMed ID: 21467941
[TBL] [Abstract] [Full Text] [Related]
13. Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines.
Peters GJ; Van Moorsel CJ; Lakerveld B; Smid K; Noordhuis P; Comijn EC; Weaver D; Willey JC; Voorn D; Van der Vijgh WJ; Pinedo HM
Int J Oncol; 2006 Jan; 28(1):237-44. PubMed ID: 16328001
[TBL] [Abstract] [Full Text] [Related]
14. Irofulven cytotoxicity depends on transcription-coupled nucleotide excision repair and is correlated with XPG expression in solid tumor cells.
Koeppel F; Poindessous V; Lazar V; Raymond E; Sarasin A; Larsen AK
Clin Cancer Res; 2004 Aug; 10(16):5604-13. PubMed ID: 15328203
[TBL] [Abstract] [Full Text] [Related]
15. Combinatorial treatment of ovarian cancer cells with harringtonine and cisplatin results in increased cisplatin-DNA adducts.
Yunmbam MK; Guo Y; Miller MR; Yu JJ
Oncol Rep; 2004 Apr; 11(4):833-8. PubMed ID: 15010881
[TBL] [Abstract] [Full Text] [Related]
16. Clear cell tumors have higher mRNA levels of ERCC1 and xpb than other histological types of epithelial ovarian cancer.
Reed E; Yu JJ; Davies A; Gannon J; Armentrout SL
Clin Cancer Res; 2003 Nov; 9(14):5299-305. PubMed ID: 14614013
[TBL] [Abstract] [Full Text] [Related]
17. Loss of heterozygosity of nucleotide excision repair factors in sporadic ovarian, colon and lung carcinomas: implication for their roles of carcinogenesis in human solid tumors.
Takebayashi Y; Nakayama K; Kanzaki A; Miyashita H; Ogura O; Mori S; Mutoh M; Miyazaki K; Fukumoto M; Pommier Y
Cancer Lett; 2001 Dec; 174(2):115-25. PubMed ID: 11689286
[TBL] [Abstract] [Full Text] [Related]
18. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.
Erba E; Bergamaschi D; Bassano L; Damia G; Ronzoni S; Faircloth GT; D'Incalci M
Eur J Cancer; 2001 Jan; 37(1):97-105. PubMed ID: 11165136
[TBL] [Abstract] [Full Text] [Related]
19. Increased mRNA levels of xeroderma pigmentosum complementation group B (xpb) and Cockayne's syndrome complementation group B (CSB) without increased mRNA levels of multidrug-resistance gene (MDR1) or metallothionein-II (MT-II) in platinum-resistant human ovarian cancer tissues.
Dabholkar M; Thornton K; Vionnet J; Bostick-Bruton F; Yu JJ; Reed E
Biochem Pharmacol; 2000 Dec; 60(11):1611-9. PubMed ID: 11077043
[TBL] [Abstract] [Full Text] [Related]
20. Evidence for in the appearance of mRNAs of nucleotide excision repair genes, in human ovarian cancer tissues.
Reed E; Dabholkar M; Thornton K; Thompson C; Yu JJ; Bostick-Bruton F
Oncol Rep; 2000; 7(5):1123-8. PubMed ID: 10948350
[TBL] [Abstract] [Full Text] [Related]
[Next]